Thermo Fisher Scientific

  • Categories
    • Advancing Materials
    • Advancing Mining
    • AnalyteGuru
    • Analyzing Metals
    • Ask a Scientist
    • Behind the Bench
    • Biotech at Scale
    • Clinical Conversations
    • Examining Food
    • Identifying Threats
    • Illuminating Semiconductors
    • Life in Atomic Resolution
    • Life in the Lab
    • OEMpowered
    • The Connected Lab
  • About Us
  • Contact
Accelerating ScienceBehind the Bench / Infectious Diseases / Targeted Gene Editing with CRISPR Technology

Targeted Gene Editing with CRISPR Technology

Written by Behind The Bench Staff | Published: 01.12.2022

Combating Life-Threatening Viral Infections – HIV-1

Using CRISPR and Cas Protein to Identify and Edit DNA Sequences

CRISPR technology is a revolutionary gene editing tool that holds great promise for combating life-threatening viral infections. CRISPR stands for clustered regularly interspaced short palindromic repeats, which are part of a genome editing system that evolved naturally in bacteria [1,2]. Geneticists can use CRISPR technology to recognize a specific DNA sequence and edit it with a CRISPR-associated ribonuclease, or Cas protein.

To direct editing specificity, the Cas protein is complexed with a small guide RNA (gRNA) that is complementary to the target sequence. The Cas protein cuts both DNA strands when the associated gRNA binds to the target sequence, and innate cellular DNA repair mechanisms can be harnessed to introduce a nucleotide-specific change, remove an entire DNA segment, or replace region of DNA with a customized sequence. Sanger sequencing by capillary electrophoresis (CE) is typically performed afterwards to assess the accuracy and efficiency of the gene editing process.

CRISPR Gene Editing as a Novel Approach to Durable HIV-1 Control

Approximately 38 million people around the world live with human immunodeficiency virus (HIV), and up to one million individuals die of illness due to acquired immunodeficiency syndrome (AIDS) each year [3]. While antiretroviral therapy (ART) can significantly inhibit HIV-1 replication, it does not remove proviral HIV-1 DNA from the host genome. The latent virus persists in host cells and can readily reactivate if ART is discontinued, which can result in progression to AIDS. Long-term remission of HIV-1 infection is exceedingly rare [4,5], and there is currently no cure for AIDS.Strand of DNA

HIV-1 Therapy with the CRISPR-Cas9 System

Cas9 is an RNA-guided endonuclease originally discovered in Streptococcus pyogenes, and gene editing with the CRISPR-Cas9 system has demonstrated potential as a way to eliminate the need for ART to treat HIV-1 infection in humans [6,7]. Researchers in the Pillai laboratory at the University of California San Francisco, the Vitalant Research Institute, and Los Alamos National Laboratory devised a dual-target editing strategy to prevent HIV-1 replication in human T cells and counteract infection of uninfected cells in vitro.

Related: Genotyping of HIV-1 to Detect Drug Resistance

Human Jurkat cells infected with HIV-1 were transfected with a lentiviral vector that expressed the Staphylococcus aureus Cas9 enzyme SaCas9 and two gRNAs that targeted highly conserved regions in the latent HIV-1 gag gene. The team designed gRNAs for highly conserved regions of the HIV genome to maximize the number of strains they could target and minimize the likelihood of off-target editing events. The lentiviral vector was also engineered to express a gRNA that recognized a sequence in the human CXCR4 gene to reduce expression of the CXCR4 receptor responsible for HIV-1 entry into CD4+ T cells.

Prior to gene editing, the team performed PCR to amplify genomic regions that contained gRNA target sequences and analyzed the amplicons with high-resolution Sanger sequencing. They screened a total of 20 gRNA candidates to identify gRNAs that would be both effective and unlikely to cause off-target editing events. Once CRISPR-Cas9 editing was complete, Sanger sequencing was performed again to determine whether the dual-target strategy was successful. The Sanger sequencing output was used as input for tracking of indels by decomposition (TIDE) analysis, which revealed the frequency of small insertions and deletions (indels) generated by the CRISPR-Cas9 system.

CRISPR-Cas9 System

Reduce Virus Production and Achieve Remission

Targeting the HIV-1 gag gene alone reduced virus production by 78%, while targeting only the human CXCR4 gene reduced surface expression of the CXCR4 receptor by 35%. The team found that targeting the gag and CXCR4 genes simultaneously was the most effective strategy for achieving remission. The complete CRISPR-Cas9 system both inactivated HIV-1 production in infected human T cells and rendered uninfected cells resistant to the virus. The team also developed a mathematical model that predicted the two-pronged editing approach would enable 513 days of remission in vivo in the absence of ART and 591 days of remission after ART cessation.

Indefinite Remission Might Be Possible

The authors of the study concluded that indefinite remission might be possible with multiple rounds of CRISPR-Cas9 gene therapy. Their work demonstrates that a dual-gene CRISPR-Cas9 editing strategy has the potential to revolutionize clinical HIV-1 management by eliminating the need for antiretroviral drugs.colleagues at computer together exploring possibilities

Sanger Sequencing by CE and Fragment Analysis

The Gold Standard For Gene Editing Confirmation

Accurate, Simple, Cost-Effective, Long Read Lengths

Sanger sequencing by capillary electrophoresis (CE) is the gold standard for gene editing confirmation due to its accuracy, simplicity, cost-effectiveness, and long read lengths. Sanger sequence analysis is straightforward.

Assess Editing Efficiency with Fragment Analysis by CE

In addition, fragment analysis by CE enables rapid detection of insertions and deletions with single base pair resolution. Since DNA repair during CRISPR-mediated gene editing in primary transformed cells is not entirely efficient or accurate, fragment analysis and Sanger sequencing are often performed to assess editing efficiency. CE is also useful for determining the frequency of successful editing events in secondary clones.

Related: CRISPR Gene Editing Confirmation With Sanger Sequencing

Applied Biosystems™ genetic analyzers are trusted CE systems for Sanger sequencing and fragment analysis, and they drive today’s most powerful CRISPR gene editing applications. Innovations like the SeqScreener app on the Thermo Fisher™ Connect Platform have been designed from the ground up for determining the range and frequency of CRISPR-Cas9 gene edits.

Related: Your Vital Research Data is Secure with Thermo Fisher Connect

Learn More: thermofisher.com/seqscreener – Sanger sequencing and fragment analysis for CRISPR-Cas9 gene editing confirmation and Applied Biosystems genetic analyzers.

Check out more posts like this one on our Behind the Bench blog.

 

References

 

  1. Jansen R, van Embden JDA, Gaastra W, Schouls LM (2002) Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43(6):1565-1575.
  2. Andersson AF and Banfield JF (2008) Virus population dynamics and acquired virus resistance in natural microbial communities. Science 320(5879):1047-1050.
  3. Joint United Nations Program on HIV/AIDS (2020) Global HIV and AIDS statistics—fact sheet (https://www.unaids.org/en/resources/fact-sheet).
  4. Hutter G, Nowak D, Mossner M et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem cell transplantation. New Engl J Med 360:692-698.
  5. Gupta RK, Abdul-Jawad S, McCoy LE et al. (2019) HIV-1 remission following CCR5∆32/∆32 haematopoietic stem cell transplantation. Nature 568:244-248.
  6. Chavez LR, Reddy, NR, Raymond KA et al. (2020) Durable control of HIV-1 using a Staphylococcus aureus Cas9-expressing lentivirus co-targeting viral latency and host susceptibility. bioRχiν preprint (https://doi.org/10.1101/2020.08.10.243329).
  7. Xu L, Wang J, Liu Y et al. (2019) CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. New Engl J Med 381:1240-1247).
Share this article
72
SHARES
FacebookLinkedinTwitterMail

Comments

  1. cookie clicker says

    January 18, 2022 at 8:04 am

    Good! Congratulations on your research achievements

    Reply
  2. Mehado says

    March 3, 2022 at 11:16 am

    I really appreciate the efforts. This tool holds great promise for combating life-threatening viral infections may be very helpful.

    Reply
  3. Mechado says

    March 3, 2022 at 11:17 am

    I really appreciate the efforts. This tool holds great promise for combating life-threatening viral infections may be very helpful.

    Reply
  4. https://www.zagrosllc.com/ says

    May 18, 2022 at 4:01 pm

    Thanks for sharing this great article.

    Reply
  5. https://www.atoccleaningservices.com/ says

    May 25, 2022 at 5:05 pm

    Awesome post! Nice share.

    Reply
  6. click here says

    May 25, 2022 at 5:06 pm

    Glad to check this awesome site.

    Reply
  7. visit us says

    June 1, 2022 at 2:37 pm

    I Like how clean and neat your blog is. Thanks for this.

    Reply
  8. GIS Infomedia says

    June 15, 2022 at 8:35 am

    I worked in a lab that’s helping perfect and understand CRISPR and this video literally makes me cry. its one of the most wonderful things we’ve ever accomplished. This changes the world in so many ways. But at the same time its on of the most ethically odd things we’ve ever encountered. Also don’t be fooled, were still a decade away from editing your genome at the doctor’s office. Or really doing anything at all.

    Reply
  9. http://www.nashvillehoodcleaning.net/ says

    July 7, 2022 at 2:33 pm

    CRISPR/Cas9 targeted genome editing techniques have been developed from systems that evolved in prokaryotes to help provide immunity from viruses such as bacteriophages and other foreign DNA, such as plasmids (Horvath and Barrangou, 2010).

    Reply
  10. prosolarstl.com/ says

    August 8, 2022 at 3:31 pm

    Nice post! It’s a great share.

    Reply
  11. drywall professional says

    November 3, 2022 at 10:52 pm

    This crispr technology seems very interesting.

    Reply
  12. https://ibisegozi.com/ says

    November 17, 2022 at 7:41 am

    That’s important data to know.

    Reply
  13. https://ibisegozi.com/ says

    November 17, 2022 at 7:42 am

    Glad to know the details here.

    Reply
  14. epoxyfloorsirving.com/ says

    November 21, 2022 at 11:59 am

    This is amazing! Thanks for the info.

    Reply
  15. info says

    November 22, 2022 at 9:14 am

    That’s great! keep on posting.

    Reply
  16. www.pghguttercleaning.com says

    November 23, 2022 at 1:11 am

    Superb writing and research. Thanks for sharing information about this and hope to learn more on this page. On the other note, I also like insights about gutter cleaning.

    Reply
  17. www.pghguttercleaning.com says

    November 23, 2022 at 1:13 am

    Wow! Superb writing and research. Thanks for sharing information about this and hope to learn more on this page. On the other note, I also like insights about gutter cleaning.

    Reply
  18. Click here says

    November 23, 2022 at 1:14 am

    Wow! Superb writing and research. Thanks for sharing information about this and hope to learn more on this page. On the other note, I also like insights about land surveyors

    Reply
  19. Click here says

    November 23, 2022 at 1:35 am

    Wow! Superb writing and research. Thanks for sharing information about this and hope to learn more on this page. On the other note, I also like insights about cab services.

    Reply
  20. our it team says

    December 1, 2022 at 1:20 pm

    Is CRISPR gene targeting?

    Reply
  21. FRP grate says

    December 2, 2022 at 5:48 pm

    What a great breakthrough in technology!

    Reply
  22. our it team says

    December 12, 2022 at 8:01 am

    CRISPR/Cas9 edits genes by precisely cutting DNA and then letting natural DNA repair processes to take over.

    Reply
  23. www.windowcleanersburnaby.com says

    December 27, 2022 at 5:26 am

    I’m very very happy, because i find this article, thank you very much has been sharing this information!

    Reply
  24. Levi says

    January 9, 2023 at 4:25 pm

    Despite the fact that great efforts have been made in the prevention and therapy of HIV-1 infection, HIV-1/AIDS remains a major threat to global human health. Highly active antiretroviral therapy (HAART) can suppress virus replication, but it cannot eradicate latent viral reservoirs in HIV-1/AIDS patients. Recently, the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) system has been engineered as an effective gene-editing technology with the potential to treat HIV-1/AIDS. It can be used to target cellular co-factors or HIV-1 genome to reduce HIV-1 infection and clear the provirus, as well as to induce transcriptional activation of latent virus in latent viral reservoirs for elimination. This versatile gene editing technology has been successfully applied to HIV-1/AIDS prevention and reduction in human cells and animal models. Here, we update the rapid progress of CRISPR/Cas9-based HIV-1/AIDS therapy research in recent years and discuss the limitations and future perspectives of its application.

    Reply
    • business owner says

      January 12, 2023 at 11:05 pm

      I never heard about crisp technology before. Interesting.

      Reply
  25. business owner says

    January 12, 2023 at 11:04 pm

    I never heard about crisp technology before. Interesting.

    Reply
  26. sierravistaremodeling.com/ says

    January 18, 2023 at 2:05 pm

    Thank you for sharing this great article.

    Reply
  27. Marla says

    March 16, 2023 at 1:06 am

    I tried to use Crisp technology in Columbus. This is very promising!

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Unsolved Cases: Lawfully Owed DNA May Hold the Answers
Tips for a Successful Dry-Off Using Selective Dry Cow Therapy (SDCT)

Privacy StatementTerms & ConditionsLocationsSitemap

© 2025 Thermo Fisher Scientific. All Rights Reserved.

Talk to us

Notifications

Get news and research reviews on the topic of your choice, right in your inbox.

Subscribe Now

  • This field is for validation purposes and should be left unchanged.

×
  • Tweet
  • Facebook
  • Tweet
  • Facebook